Cancer Genomics Group

Strategic Goals

1. Somatic mutation profiling of tumor genomes to stratify patients entering clinical trials.
2. Identification of somatic mutations involved in mechanisms of sensitivity or resistance to PI3K inhibitors in breast cancer and glioma.
3. Offer genomic services to basic and clinical researchers in VHIO.

Current objectives

• Our goal in 2010 is to set up the MassARRAY (SEQUENOM) and Genome Analyzer IIx (Illumina) technologies to study cancer genomes in the context of clinical trials as well as in basic research projects. We will also establish DNA extraction and bias-free whole genome amplification systems from FFPE tissues as well as from low cellularity samples.